Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2023 - 2025)

Monte Rosa Therapeutics' Total Current Liabilities history spans 3 years, with the latest figure at $64.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 59.09% year-over-year to $64.2 million; the TTM value through Dec 2025 reached $64.2 million, down 59.09%, while the annual FY2025 figure was $64.2 million, 59.09% down from the prior year.
  • Total Current Liabilities reached $64.2 million in Q4 2025 per GLUE's latest filing, up from $61.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $156.9 million in Q4 2024 to a low of $19.1 million in Q2 2023.
  • Average Total Current Liabilities over 3 years is $51.5 million, with a median of $42.1 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 236.85% in 2024, then tumbled 59.09% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $46.6 million in 2023, then surged by 236.85% to $156.9 million in 2024, then crashed by 59.09% to $64.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Total Current Liabilities are $64.2 million (Q4 2025), $61.4 million (Q3 2025), and $41.9 million (Q2 2025).